Pharma Focus Asia
KP - Choose our fully recyclable blister films

Driving value creation through medical affairs in China

Summary:

After more than three decades of fast economic growth, China has entered the “new normal” stage, marked by a moderate and stable domestic GDP growth rate. Healthcare has been elevated to a national level agenda by the current leadership with the releasing of “China Health 2030”.

In addition, “Made in China 2025” (shown in Figure 1) has also demonstrated Chinese government’s mission to foster innovation while continuing to enhance drug safety and improve healthcare service quality.

Download '.pdf' Format of the whitepaper.

Download Whitepapers
Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayMerck - Mobius® productsThermo Fisher Scientific - Peptones5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 2023Reuters Events - Pharma Customer Engagement USA 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023CHEMICAL INDONESIA 2024INALAB 2024